# Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

> **NCT02053246** · PHASE4 · TERMINATED · sponsor: **University of Florida** · enrollment: 11 (actual)

## Conditions studied

- Pulmonary Hypertension
- Diastolic Heart Failure
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Nebivolol

## Key facts

- **NCT ID:** NCT02053246
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study funding ended before recruitment completed.
- **Last updated:** 2022-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053246, "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02053246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*